Sequential delayed <sup>18</sup>F-FDG PET/CT examinations may increase specificity of this scan and provide information for the differentiation benign and malignant lymph nodes in the cases of head and neck cancer.
We conducted a prospective, pilot study of carotid artery inflammation using <sup>18</sup>F-labeled 2-fluoro-2-deoxy-d-glucose ([<sup>18</sup>F]FDG) PET/CT imaging pre- and 3 months post-RT in head-and-neck cancer (HNC) patients.
Incidental findings on 18-FDG PET-CT in head and neck cancer. A retrospective case-control study of incidental findings on 18-FDG PET-CT in patients with head and neck cancer.
The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer.
A radiomics signature built from <sup>18</sup>F-FDG PET and contrast-enhanced CT features correlates with <sup>18</sup>F-FMISO TBR<sub>max</sub> in head and neck cancer patients, providing significantly better performance with respect to models based on <sup>18</sup>F-FDG PET only.
This study illustrates how the incidental findings discovered on FDG PET/CT frequently necessitate additional evaluations unrelated to the index head and neck cancer.
The utility of fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to predict outcome has been well-established for patients undergoing definitive radiation in the initial management of head and neck cancer.